Vaxcyte, Inc. — Director's Dealing 2025

Jan 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-01-21

Reporting Person: GUGGENHIME ANDREW (PRESIDENT AND CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-21	Common Stock	M	8000	$5.35	Acquired	117491	Direct
2025-01-21	Common Stock	S	5318	$86.084	Disposed	112173	Direct
2025-01-21	Common Stock	S	1999	$87.247	Disposed	110174	Direct
2025-01-21	Common Stock	S	683	$87.70	Disposed	109491	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-21	Stock Option (right to buy)	$5.35	M	8000	Disposed	2030-05-11	Common Stock (8000)	Direct

Footnotes

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $85.54 to $86.455. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $86.58 to $87.545. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $87.58 to $87.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F5: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.